First of all, it should be emphasized that both plasma exchange and immunosorbent therapy are artificial methods to forcibly remove a large amount of disease-causing substances from the blood to achieve rapid relief, but after the disease-causing substances are removed, the body will continue to produce them. Therefore, plasma exchange and immunosorbency are only a “superficial” measure, but must be combined with drug therapy to inhibit the production of abnormal disease-causing substances in the body from the source, in order to consolidate the efficacy and “treat the surface” and “treat the root”. Secondly, it is very important to master the timing of treatment. In the early stage of the disease, when the lesions of important organs are still in the reversible stage and have not been completely destroyed by the disease-causing substances, timely active plasma replacement or immunosorbent therapy can often get better results with half the effort. On the contrary, if plasma exchange or immunosorbent therapy is necessary at the end stage of the disease, even if the disease-causing substances are effectively removed from the body, the damaged organs are likely to be irreparably damaged, and half the effort is needed to achieve satisfactory results. In addition, during the acute phase of the disease, plasma exchange or immunosorbent treatment is not enough. On the other hand, high concentrations of pathogenic substances are present not only in the patient’s blood but also in extravascular tissues. After one treatment, although the concentration of pathogenic substances in the blood has been cleared and decreased, the body will subsequently produce new pathogenic substances, and the relatively high concentration of pathogenic substances in the tissues will be transferred to the blood, causing the concentration of pathogenic substances in the blood to rise again, resulting in a “rebound” phenomenon. Therefore, in the acute phase of the disease, a single high-dose treatment is not the best solution, but regular and repeated plasma exchange or immunosorbent therapy, together with drug therapy, is the most effective. Finally, it should be noted that the safety of plasma exchange or immunosorbent therapy still needs to be taken into account and the indications for treatment must be strictly controlled. Plasma replacement requires large amounts of plasma and plasma substitutes. Although plasma substitutes are relatively economical and available in sufficient quantities, many important plasma components are missing. However, many important plasma components are missing, so the amount of plasma substitute supplementation should be controlled within a certain ratio. Plasma replacement therapy should be supplemented with fresh frozen plasma and, if necessary, coagulation factor products. In addition, transfusion of large amounts of blood products carries the risk of infection with blood-borne infectious diseases and allergies. Immunosorbency generally does not require plasma supplementation, but there is still some risk of infection and allergy due to the removal of large amounts of immunoglobulins from the body and the need for appropriate supplementation of normal human immunoglobulins. This is coupled with the possible complications of the extracorporeal circulation therapy technique itself such as bleeding and infection. On the other hand, plasma exchange is expensive, and immunosorbency is even more expensive. Therefore, plasma exchange or immunosorbent therapy must be strictly controlled and not abused.